Skip to main content
Clinical Trials/NCT06462027
NCT06462027
Suspended
Phase 1

A Single-center, Randomized, Placebo Controlled Pilot Study of Packed Red Blood Cell Transfusion During Prolonged Adult In-hospital Cardiac Arrest

NYU Langone Health1 site in 1 country30 target enrollmentJune 1, 2026

Overview

Phase
Phase 1
Intervention
Packed Red Blood Cells (1 unit)
Conditions
Cardiac Arrest
Sponsor
NYU Langone Health
Enrollment
30
Locations
1
Primary Endpoint
Time (in mins) to administration of Packed Red Blood Cells (PRBC)
Status
Suspended
Last Updated
23 days ago

Overview

Brief Summary

The purpose of this pilot interventional study is to collect preliminary data on administering packed red blood cell (PRBC) during cardiac arrest (CA). The primary objective is to assess the feasibility of PRBC transfusion during cardiac CA to help optimize the methods required to augment cerebral and other vital organ oxygen delivery during cardiopulmonary resuscitation (CPR). The secondary objectives are to assess the effect of PRBC transfusion during prolonged cardiac arrests on cerebral oxygenation, end tidal carbon dioxide (ETCO2), return of spontaneous circulation (ROSC), survival to discharge, biomarkers of neural injury and inflammation, and neurological outcomes at hospital discharge, 30 days post-CA, and 90 days post-CA.

Registry
clinicaltrials.gov
Start Date
June 1, 2026
End Date
September 1, 2027
Last Updated
23 days ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult patients, age ≥18 and \<85 years
  • Experience prolonged, non-trauma-related in-hospital cardiac arrest, defined by cessation of heartbeat and respiration requiring CPR for at least 10 minutes

Exclusion Criteria

  • Age \<18 years old
  • Age \> 85 years old
  • Patients with DNR/DNI orders (Do Not Resuscitate/Do Not Intubate)
  • Patients admitted to the hospital with a cardiac arrest arising from trauma
  • Patients who achieve return of spontaneous circulation within 10 minutes of CPR
  • Inability to start study product administration within 20 minutes of cardiac arrest onset
  • Prisoners
  • Women who are known to be pregnant
  • Patients with a history of RBC antibodies or positive antibody screen prior to enrollment in the study, unless previously cross-matched units are available for transfusion.
  • Patients with ultrasound evidence of right ventricular dilatation at time of CA

Arms & Interventions

Packed Red Blood Cells (1 unit)

500 mL of packed red blood cells

Intervention: Packed Red Blood Cells (1 unit)

Saline solution

Treatment of 500 mL of normal saline.

Intervention: Saline

Packed Red Blood Cells (2 units)

1000 mL of packed red blood cells

Intervention: Packed Red Blood Cells (2 units)

Outcomes

Primary Outcomes

Time (in mins) to administration of Packed Red Blood Cells (PRBC)

Time Frame: During Cardiopulmonary Resuscitation (CPR) (up to 20 minutes)

Change in frequency of right ventricular (RV) dilatation

Time Frame: Baseline, up to 20 minutes post administration of PRBC

Proportion of patients with unfavorable neurological outcomes

Time Frame: Up to 30 days post-Cardiac Arrest (CA)

The Cerebral Performance Category (CPC) score is a five-point scale used to assess neurological outcome after cardiac arrest and other events. Scores range from 1 to 5, a score of 1 or 2 is considered a favorable outcome, and scores of 3, 4, or 5 are considered an unfavorable outcome (severe neurological disability, persistent vegetative state or death).

Frequency of antibody-mediated transfusion reactions

Time Frame: 6-72 hours after Return of Spontaneous Circulation (ROSC)

Outcome measure will be evaluated for the occurrence of intravascular and extravascular hemolytic reactions by measuring fibrinogen, D-dimer, platelet count, peripheral blood smear, and serum haptoglobin.

Frequency of non-immune reactions

Time Frame: 6-72 hours after ROSC

Non-immune reactions include Transfusion Associated Circulatory Overload (TACO) and Transfusion-Related Acute Lung Injury (TRALI) as determined by the Data Safety Monitoring Committee (DSMC).

All-cause mortality

Time Frame: Up to 30 days after the last day of study participation

Mortality due to all causes

Secondary Outcomes

  • Rate of survival(At time of hospital discharge (approximately 12 days))
  • Rate of survival(30 days post-CA)
  • CPC score(At time of hospital discharge (approximately 12 days))
  • CPC score(30 days post-CA)
  • Relative change in peak rSO2(2 minutes prior to administration, 5 minutes post administration of PRBC)
  • Relative change in mean rSO2(2 minutes prior to administration, 5 minutes post administration of PRBC)
  • Rate of survival(90 days post-CA)
  • Relative change in peak end tidal carbon dioxide (ETCO2)(2 minutes prior to administration, 5 minutes post administration of PRBC)
  • CPC score(90 days post-CA)
  • Absolute change in peak regional oxygen saturation (rSO2)(2 minutes prior to administration, 5 minutes post administration of PRBC)
  • Absolute change in mean rSO2(2 minutes prior to administration, 5 minutes post administration of PRBC)
  • Relative change in mean ETCO2(2 minutes prior to administration, 5 minutes post administration of PRBC)
  • Proportion of patients with release of pro-inflammatory cytokines(6-72 hours after ROSC)
  • Proportion of patients with release markers of brain injury(6-72 hours after ROSC)
  • Rate of ROSC(During CPR (up to 20 minutes))

Study Sites (1)

Loading locations...

Similar Trials